MAP2K2 and laryngotracheoesophageal cleft: While some of the kinase inhibitors are already exploited for LC therapy, that is, four in AD (MET, EGFR, NTRK1 and RET) and four in SQ (EGFR, MAP2K2, RET and BRAF), there are another seven kinase targets (SRC, JAK1, TYK2, FGFR1/2, CDK6 and PDGFRA) which are used for other indications such as clear cell renal cell carcinoma, osteosarcoma, acute myeloid leukaemia, urothelial bladder cancer, bile duct and breast cancer (Table S8).